Qu Biologics.png
Dr. Matt Cahill Appointed Chief Operating Officer of Qu Biologics
January 23, 2023 08:00 ET | Qu Biologics, Inc.
BURNABY, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics.png
Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform
December 14, 2022 08:00 ET | Qu Biologics, Inc.
BURNABY, British Columbia, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics.png
Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly
October 17, 2022 08:00 ET | Qu Biologics, Inc.
BURNABY, British Columbia, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics.png
Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer
September 26, 2022 08:00 ET | Qu Biologics, Inc.
BURNABY, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy...
Qu Biologics.png
Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead
July 20, 2022 08:00 ET | Qu Biologics, Inc.
BURNABY, British Columbia, July 20, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
Qu Biologics.png
Qu Biologics Closes USD$12M Equity Financing
March 21, 2022 08:00 ET | Qu Biologics, Inc.
BURNABY, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
Qu Biologics.png
Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress
July 13, 2021 08:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics.png
Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu’s First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment
June 23, 2021 08:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, June 23, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
Qu Biologics.png
Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021
June 09, 2021 09:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics.png
Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis
May 12, 2021 09:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...